Eradication of tuberculosis (TB), the world's leading cause of death due to infectious disease, requires a highly efficacious TB vaccine. Many TB vaccine candidates are in preclinical and clinical development but only a few can be advanced to large-scale efficacy trials due to limited global resources. We aimed to perform a statistically rigorous comparison of the antigen-specific T cell responses induced by six novel TB vaccine candidates and the only licensed TB vaccine, Bacillus Calmette-Guérin (BCG). We propose that the antigen-specific immune response induced by such vaccines provides an objective, data-driven basis for prioritisation of vaccine candidates for efficacy testing. We analyzed frequencies of antigen-specific CD4 and CD8 T cells expressing IFNγ, IL-2, TNF and/or IL-17 from adolescents or adults, with or without Mycobacterium tuberculosis (M.tb) infection, who received MVA85A, AERAS-402, H1:IC31, H56:IC31, M72/AS01E, ID93+GLA-SE or BCG. Two key response characteristics were analyzed, namely response magnitude and cytokine co-expression profile of the memory T cell response that persisted above the pre-vaccination response to the final study visit in each trial. All vaccines preferentially induced antigen-specific CD4 T cell responses expressing Th1 cytokines; levels of IL-17-expressing cells were low or not detected. In M.tb-uninfected and -infected individuals, M72/AS01E induced higher memory Th1 cytokine-expressing CD4 T cell responses than other novel vaccine candidates. Cytokine co-expression profiles of memory CD4 T cells induced by different novel vaccine candidates were alike. Our study suggests that the T cell response feature which most differentiated between the TB vaccine candidates was response magnitude, whilst functional profiles suggested a lack of response diversity. Since M72/AS01E induced the highest memory CD4 T cell response it demonstrated the best vaccine take. In the absence of immunological correlates of 3 protection the likelihood of finding a protective vaccine by empirical testing of candidates may be increased by the addition of candidates that induce distinct immune characteristics. Author summary Tuberculosis (TB) causes more deaths than any other single infectious disease, and a new, improved vaccine is needed to control the epidemic. Many new TB vaccine candidates are in clinical development, but only one or two can be advanced to expensive efficacy trials. In this study, we compared magnitude and functional attributes of memory T cell responses induced in recently conducted clinical trials by six TB vaccine candidates, as well as BCG. The results suggest that these vaccines induced CD4 and CD8 T cell responses with similar functional attributes, but that one vaccine, M72/AS01E, induced the largest responses. This finding may indicate a lack of diversity in T cell responses induced by different TB vaccine candidates. A repertoire of vaccine candidates that induces more diverse immune response characteristics may increase the chances of finding a protective vaccine against TB.
Introduction
is an infectious disease of major global importance. More than ten million people were diagnosed with TB disease in 2016 and 1.67 million died [1] . Current efforts to curb the TB epidemic are insufficient to achieve the 2035 targets set by the World Health Organization, of a 95% reduction in TB deaths and a 90% reduction in the TB incidence rate, compared with levels in 2015 [1] . There is widespread consensus, supported by epidemiological modeling, that a highly efficacious TB vaccine is necessary to achieve these TB control objectives [2, 3] .
Thirteen novel TB vaccine candidates were being assessed at various stages in phase 1-3 clinical trials in 2017. However, whilst criteria have been proposed to guide advancement of vaccine candidates to efficacy testing, these are neither unanimously agreed upon nor used [4] . There is also limited stakeholder effort to harmonize or standardize clinical trial design and, as a result, different vaccine candidates are typically assessed in unrelated trials with unique design features that preclude direct comparison of results. This is also the case for assessment of immunological outcomes of TB vaccine trials. Most clinical trials measure vaccine-induced CD4 and/or CD8 cells expressing the Th1 cytokines IFN, TNF and IL-2, on the basis that these cells are necessary, although not sufficient, for protective immunity against Mycobacterium tuberculosis (M.tb) in animal models and humans (reviewed in [5, 6] ). However, the types of assays, methodologies and protocols employed by different investigators to measure Th1-cytokine expressing T cells vary considerably [7] . Direct comparison of the magnitude, character and durability of antigenspecific immune responses induced by different TB vaccine candidates is therefore highly problematic. We propose that this is an important gap in knowledge required to guide advancement of vaccine candidates through the clinical development pipeline.
To facilitate rational, data-driven decisions about vaccine candidate advancement, we compared Bacillus Calmette-Guérin (BCG) [8] and six novel TB vaccine candidates, including MVA85A [9, 10] , AERAS-402 [11] , H1:IC31 [12] , M72/AS01E [13, 14] , ID93+GLA-SE [15] and H56:IC31 [16] , by their induced antigen-specific CD4 and CD8 T cell responses from data generated in human clinical trials previously completed at the South African TB Vaccine Initiative. The immune responses were measured using the same immunological assay [17, 18] , enabling direct comparisons between vaccines. We aimed to define group(s) of vaccines that induced distinct immune responses. Within a group, the vaccines would induce similar immune responses, thus motivating further testing for only one vaccine per group by applying an objective, data-based criterion for vaccine prioritisation.
We identified appropriate statistical approaches and performed an analysis of antigenspecific T cell responses to each antigen in the different vaccine candidates. Comparing the magnitude and cytokine co-expression profiles of vaccine-induced memory CD4 and CD8 T cell responses that persisted to the final study visit in each trial, we revealed considerable homogeneity in vaccine-induced Th1 memory response profiles, particularly in individuals with underlying M.tb infection. Our study provides a framework for interpreting immunological characteristics that may be useful for prioritization of vaccine candidates for advancement through the development pipeline.
Results
Immune responses from a total of 225 (117 M.tb-uninfected and 108 M.tb-infected) HIVuninfected individuals vaccinated with one of six novel TB vaccine candidates, and 27 revaccinated with BCG, were analyzed ( Tables 1 and 2) . Study participants were either adolescents or adults. Immune responses were measured by a whole blood intra-cellular staining assay (WB-ICS) with multiparameter flow cytometry [17, 18] . For each vaccine, frequencies of CD4 and CD8 T cells that produced IFNγ, TNF, IL-2 and/or IL-17 in response to antigens in that vaccine were measured. • Sub-unit
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(2) Rv2608 1 We also included the T cell response to natural M.tb infection, assessed by stimulation of whole blood from 21 QFT+ donors with a peptide pool (megapool) of the 122 most immunogenic peptides in M.tb [19] , as a comparator. 2 IM: intramuscular; ID: intradermal.
Pre-vaccination antigen-specific T cell responses
Many individuals in countries endemic for TB, such as South Africa, are immunologically sensitized to mycobacteria due to a combination of infant BCG vaccination, exposure to environmental non-tuberculous mycobacteria and/or natural M.tb infection [20] . To investigate effects of this on pre-vaccination T cell responses, we examined frequencies of Th1-cytokine expressing T cells specific to antigens in each vaccine. CD4 T cell responses to all vaccine antigens were low in M.tb-uninfected participants, although responses to antigens in H56:IC31, H1:IC31 and M72/AS01E were detected at frequencies significantly higher than 0.005%, which we defined as the positive response criterion (Fig 1A and S1   Fig) . By contrast, pre-vaccination CD4 responses to antigens in AERAS-402, MVA85A and ID93+GLA-SE were not significantly larger than 0.005%.
In M.tb-infected persons, Th1 responses to antigens in all vaccines except MVA85A were detectable at frequencies significantly higher than 0.005%, although the highest responses were observed for BCG and the megapool (Fig 1A) . The pre-vaccination responses were higher than in M.tb-uninfected individuals, but only the difference for M72/AS01E was Pre-vaccination CD8 T cell responses to all vaccine antigens as well as the M.tb megapool were low and did not significantly exceed 0.005% for any vaccine in either M.tb-uninfected or -infected participants (Fig 1B and S1B Fig) .
Longitudinal vaccine-induced T cell responses
Next, we examined longitudinal frequencies of antigen-specific CD4 and CD8 T cell responses induced by each of the vaccines (Fig 2) , measured at various time points in each trial ( Table 2) . Vaccine-induced CD4 T cell responses were higher than CD8 T cell responses. In addition, as expected and previously described [8- 15, 21] , these responses typically peaked at the measurement timepoint immediately after vaccine administration and waned thereafter. Inter-donor variability in CD4 T cell responses to M72/AS01E, H1:IC31
and BCG was high, especially during the early effector phases of the response kinetics (Fig   2) .
Vaccine-induced memory T cell responses
To determine which vaccines induced durable T cell responses and compare the magnitude of these responses, we examined vaccine-induced memory CD4 and CD8 T cell response frequencies.
The vaccine-induced memory response is the difference between frequencies of antigen-specific Th1-cytokine producing cells at the final time point and the prevaccination timepoint in each trial.
Among novel vaccine candidates, M72/AS01E, ID93+GLA-SE and H1:IC31 induced CD4 responses that were significantly higher than pre-vaccination levels in both M.tb-uninfected and -infected individuals, with M72/AS01E inducing greater memory responses than the other novel vaccine candidates (Fig 3A and S3 Fig) . 
Cytokine co-expression profiles of vaccine-induced memory responses
An important feature of T cell responses to pathogens, including M.tb, is the cytokine coexpression profile of CD4 T cells, which may reflect the degree of T cell differentiation or quality of the response [6, 22, 23] . We analyzed cytokine co-expression profiles of the memory CD4 T cell responses induced by the vaccines. We did not include the cytokine coexpression profiles of the vaccine-induced memory CD8 T cell responses, becasue the magnitudes of the vaccine-induced CD8 memory response were either very low or not significant.
We analyzed cytokine co-expression profiles using principal components analysis (PCA)
biplots. In addition, 95% bivariate confidence areas of the mean response for each vaccine were computed using bootstrapping for the first two principal components of the vaccine- In M.tb-infected individuals, CD4 T cell responses induced by all novel TB vaccines grouped together (Fig 4B) . Furthermore, the first two principal components captured 77% of the variation, indicating that most variation was due to donor response variability rather than differences in response profiles between vaccines. Variability was largest for 
Discussion
TB vaccine development has substantially progressed in recent years, with great advances in our understanding of vaccine platforms, antigen and adjuvant selection and correlates of risk of TB disease [4] . Animal models have been standardized to enable head-to-head comparison and selection of candidate TB vaccines for advancement to phase I clinical trials [4] . Thirteen TB vaccine candidates were assessed in clinical trials in 2017 [4] , but only one or two can be advanced to large-scale efficacy trials due to limited global resources.
To provide a data-driven basis for selection of vaccine candidates for further testing in efficacy trials, we performed a comparison of antigen-specific T cell responses induced by six novel TB vaccine candidates that have been assessed in phase 1b or 2a trials at SATVI.
Three major points emerged from our study: (1) Antigen-specific T cell responses induced by the candidate TB vaccines were strongly CD4 T cell biased and predominantly expressed Our finding that vaccine-induced responses were strongly CD4 T cell-biased with little IL-17 production, and that Th1-cytokine expression profiles were similar across vaccine candidates, highlights a lack of diversity in immunological responses typically analysed in TB vaccine immunogenicity assessments. This result is perhaps not surprising given that most current TB vaccine candidates were designed to specifically target induction of IFNexpressing CD4 T cells, predicated on the well-established evidence that Th1 cells are necessary, although not sufficient, for protective immunity against M.tb, based on animal models and human studies(reviewed in [5, 6, 24] ). We acknowledge that analysis of Th1cytokine and IL-17 expressing CD4 and CD8 T cell responses may miss important T cell functions.
We did not include analysis of immunogenicity data from trials performed in age groups other than adults or adolescents, or from trials performed in current or prior TB patients. We also excluded data for other vaccine candidates assessed in clinical trials at SATVI, such as MTBVAC, VPM1002 and H4:IC31, because data from vaccinated adults or adolescents at the end of study time point were not available. The whole live mycobacterial vaccines, MTBVAC and VPM1002, are known to induce responses by a broader range of immune cells [25, 26] than those we observed and might add to the diversity of the immune responses induced by vaccine candidates. Further, we did not include analyses of antigenspecific antibody responses, which may also be important in immunity against M.tb [27, 28] , largely because antibody responses were not measured in each trial assessed here. It should be noted that high-level antigen-specific IgG responses were induced by a number of these TB vaccine candidates [14, 15] and we suggest that such responses should be measured in vaccine trials and included in future head-to-head comparisons.
Our Since the vaccine-induced memory Th1 cytokine co-expression profiles were similar, only the response magnitude separated vaccine candidates. M72/AS01E induced the largest antigen-specific CD4 T cell responses, with similar responses between other novel vaccine candidates. Therefore, based on CD4 T cell response magnitude, our study suggests that M72/AS01E demonstrated the best vaccine take, providing support for further clinical testing.
Non-immunological differences between vaccines, such as manufacturing cost, potential production capacity and ease of logistical arrangements, are also critical factors in decisions of candidate selection for further testing.
It is important to note that measures of antigen-specific T cell responses, such as the ones we analyzed, do not represent known correlates of protection against M.tb. Since immune correlates of protection against M.tb remain undefined [4, 6, 27] , the induced CD4 and CD8
T cell response producing Th1 cytokines can only be considered a measure of vaccine take.
The recent demonstration of protection afforded by BCG re-vaccination against sustained M.tb-infection [29] presents an opportunity for elucidating immune correlates of vaccineinduced protection against M.tb.
We focused our comparative analyses only on the memory T cell response that persisted to the final study visit of each clinical trial for practical reasons. This is partly because some vaccines were administered once and others twice or three times. We acknowledge that restricting our analyses to the memory response at the final study visit ignores the effector response early after vaccination and other phases of the post-vaccination response, which could have provided more heterogeneity and revealed important immune features for differentiating between the vaccine candidates. However, considering the very different study designs and the fact that the ultimate purpose of vaccination is to induce long-lasting immunological memory, we decided against analysis of earlier time points. Focusing on a single timepoint rather than a longitudinal response also strengthened the statistical analysis. It simplified interpretation and permitted standard multivariate analysis. It also increased statistical power, as it reduced the number of hypothesis tests to perform and assessed the post-vaccination timepoint with the lowest response variability. Moreover, the number of days between the final measurement and both the first vaccination and the last vaccination varied between vaccines, which confounded measurement timings with vaccine.
Regardless, it is unlikely that this would have affected our interpretation that M72/AS01E
induced the highest T cell response magnitude among novel vaccine candidates, since follow-up time in the M72/AS01E trial was well within the follow-up ranges for the other vaccines. Finally, the small sample sizes for some groups limited our ability to detect significant differences between vaccines.
Our study provides a framework for data-driven vaccine prioritisation. To facilitate these analyses in future, two factors are important. The first is standardization across trials of vaccine candidates, particularly in terms of immunological assay and time points at which immune responses are measured. A common stimulation antigen preparation, such as a "megapool" of M.tb peptides (as in [19] ), would also facilitate comparisons. The second factor is sample size. Comparing vaccines entails numerous pair-wise comparisons, and increased sample sizes would facilitate detecting and characterising differences.
In conclusion, our study suggests that the T cell response feature which most differentiated between the TB vaccine candidates was response magnitude, whilst functional profiles suggested a lack of response diversity. Since M72/AS01E induced the highest memory CD4
T cell response it demonstrated the best vaccine take. In the absence of immunological correlates of protection the likelihood of finding a protective vaccine by empirical testing of candidates may be increased by the addition of candidates that induce distinct immune characteristics.
Materials and Methods

Novel TB vaccine candidates
The dataset analyzed in this study collates vaccine-specific immune responses from different clinical trials performed at the SATVI Field Site outside Cape Town, South Africa. A summary of the different trials is presented in Table 1 .
Immune responses were measured by whole blood intra-cellular staining assay (WB-ICS)
with multiparameter flow cytometry [17, 18] . Fresh whole blood was stimulated for 12 hours with peptide pools spanning the relevant antigens ( Table 2) , or whole, live BCG.
The study protocol was approved in writing by the Human Research Ethics Committee of the University of Cape Town (HREC ref: 039/2017) and is based on anonymized data from previously published clinical studies.
Analysis design and assumptions
In some trials different vaccine doses and/or number of administrations were assessed. In these cases, to simplify interpretation of results and increase statistical power, we selected the dose and/or administration strategy that was reported as optimal in the original trial report, based on vaccine safety and tolerability as well as immunogenicity outcomes ( Table   2 ). This was generally the dose that induced the highest T cell response magnitude.
As a result of poor standardization between different clinical trials a number of important trial design features differ substantially between the different trials ( Table 2) All novel TB vaccine candidates, except AERAS-402, were given to both M.tb-uninfected and -infected individuals ( Table 2) . Participants in the AERAS-402 trial were assessed for M.tb-infection based on a TST induration of 15mm [11] . In the adult MVA85A trials infection was based on a TST induration and a positive response to ESAT-6/CFP-10 peptide pool in an in-house IFNγ ELISpot assay [10] while infection was based on a TST induration of 15mm and a positive ELISpot response to ESAT-6/CFP-10 peptide pool in the adolescent MVA85A trial [9] . All other trials used QFT with the manufacturer's 0.35IU/mL threshold.
Comparisons between vaccines were confounded by differences in vaccine-administration schedule ( Table 2 ). This study therefore compared overall vaccination strategies, rather than vaccines. Age of participants -adolescents or adults -also varied by vaccine ( Table   2) . Within this study, adolescents and adults were considered immunologically equivalent.
Pre-vaccination is the time point at which the first vaccine was given to an individual. The memory time point for CD4 and CD8 T cell response cytokine expression profiles provides the number of samples after excluding individuals based on negligible change from the prevaccination timepoint. The cut-off used for exclusion was a sum of absolute changes across the different cytokine combinations from pre-vaccination levels of 0.02.
Immunological measurements
Antigen-specific CD4 and CD8 T cells producing IFN, IL-2, TNF and/or IL-17 were measured by WB-ICS assay using flow cytometry as previously described [17, 18] .
Frequencies of T cells expressing cytokines in the unstimulated control (background) were subtracted from those in antigen-stimulated conditions; where the background response was greater than the stimulated response, the background-subtracted response was set to zero. When T cell responses for an individual vaccine were measured by separate peptide pools (representing different antigens), background-subtracted response frequencies for the antigens were summed. We defined pre-vaccination responses as the response at day zero (measured before the first vaccine administration) and the memory response as the response at the final time point. To yield the vaccine-induced memory response, we subtracted the pre-vaccination response from the memory response. Where an individual lacked a pre-vaccination response measurement, the median response for its vaccine and M.tb infection status group was used.
T cell response magnitude and cytokine co-expression profile
We analyzed the antigen-specific T cell response magnitude and the cytokine co-expression profile of antigen-specific T cells. To define the response magnitude, let mij be the frequencies of vaccine-induced memory CD4 or CD8 T cells for the j-th cytokine combination for the i-th individual. Then the vaccine-induced response size for the i-th individual is equal
. This is the net change from pre-vaccination in frequencies of antigen-specific CD4 or CD8
T cells producing IFN, IL-2 and/or TNF.
The cytokine co-expression profile aimed to reflect the T cell differentiation or quality of the antigen-specific T cell response. By using mij as defined above, the profile measure for the i-th individual for the j-th cytokine combination is given by
.
We named this the scaled response. If all the changes from pre-vaccination levels for a certain individual are positive, then the scaled response for a certain cytokine combination
gives the proportion of that change that consists of CD4 T cells producing that cytokine combination. The scaled response allows us to compare the extent to which different vaccines "favour" induction of different cytokine combinations, independently of the overall magnitude of the response induced by the vaccine. For analyses of cytokine co-expression profile, we excluded individuals for which the sum of absolute changes from pre-vaccination was less than 0.02, to ensure that the response profile was only analyzed in individuals with memory responses that meaningfully changed relative to pre-vaccination. Number of participants included in this study after exclusion are shown in S1 Table.
Univariate confidence intervals and hypothesis tests
Because sample sizes were often small ( We used trimmed means with symmetric trimming of the smallest 20% and the largest 20% of observations, because this is more robust to outliers than non-trimmed means and reflected the typical T cell response better [33] . For one-sample hypothesis tests, the false discovery rate was controlled at 0.01 using the Benjamini-Hochberg procedure [34] . For groups of pair-wise comparisons, the false discovery rate was controlled at an increased 0.05, due to the positive dependency of the tests.
Multivariate analyses
Multivariate cytokine co-expression profile data were analyzed using principal components analysis (PCA) [35, 36] and biplot axes [37] were calibrated to stretch between the mean and the maximum observed value [38] .
To assist interpretation of the biplot, confidence areas for each group were estimated by taking bootstrap samples of the mean, assuming normality of the bootstrap distribution, and applying the fact that the Mahalanoubis distance from the mean has a 2 2 distribution. The normality of the bootstrap samples may be checked by assessing the ellipticity of the contour lines of the bootstrap sample kernel density.
Axis predictivity was used to detect which variables are well represented in a biplot [39] and only variables with high axis predictivity relative to other variables have their axes displayed.
This simplifies biplot interpretation, and indicates which variables primarily drove the variability in the response. individuals that did not receive a vaccine, but whose blood was stimulated with megapool. 
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